Literature DB >> 12210046

A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro.

Erin D Hugger1, Barbara L Novak, Philip S Burton, Kenneth L Audus, Ronald T Borchardt.   

Abstract

P-glycoprotein (P-gp), a multidrug resistance (MDR) protein encoded by the MDR1 gene in humans, is responsible for the efflux of structurally diverse drugs. Previous studies in our laboratory have shown that excipients such as poly(ethylene)glycol (PEG)-300, Cremophor EL, and Tween 80 inhibit P-gp activity in Caco-2 cell monolayers. The objective of this study was to determine the effects of these excipients in an MDR1- transfected Madin Darby Canine Kidney (MDR1-MDCK) cell line and to compare the results with those obtained from Caco-2 cells. The results presented herein show that PEG-300 (20%, v/v) causes almost complete inhibition of P-gp activity in both Caco-2 and MDR1-MDCK cell monolayers, whereas Cremophor EL (0.1%, w/v) and Tween 80 (0.05%, w/v) only partially inhibit P-gp activity in Caco-2 cells. Cremophor EL (0.1%, w/v) and Tween 80 (0.05%, w/v) were inactive as P-gp inhibitors in MDR1-MDCK cell monolayers. This inability of Tween 80 and Cremphor EL to inhibit P-gp activity in MDR1-MDCK cells may be related to differences in the interactions of the surfactants with these different cell membranes. PEG-induced changes in P-gp activity are probably related to changes in the fluidity of the polar head group regions of cell membranes. Copyright 2002 Wiley-Liss Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210046     DOI: 10.1002/jps.10176

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  30 in total

Review 1.  Solubilizing excipients in oral and injectable formulations.

Authors:  Robert G Strickley
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

2.  Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates.

Authors:  Huadong Sun; K Sandy Pang
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

3.  In vitro-in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate.

Authors:  Evren Gundogdu; V Mangas-Sanjuan; Isabel Gonzalez-Alvarez; Marival Bermejo; Ercument Karasulu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-08-11       Impact factor: 2.441

Review 4.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

5.  Equivalence-by-design: targeting in vivo drug delivery profile.

Authors:  Mei-Ling Chen; Vincent H L Lee
Journal:  Pharm Res       Date:  2008-10-28       Impact factor: 4.200

6.  Vitamin E reverses multidrug resistance in vitro and in vivo.

Authors:  Jingling Tang; Qiang Fu; Yongjun Wang; Kelly Racette; Dun Wang; Feng Liu
Journal:  Cancer Lett       Date:  2013-04-23       Impact factor: 8.679

Review 7.  Preclinical formulations: insight, strategies, and practical considerations.

Authors:  Sanket M Shah; Ankitkumar S Jain; Ritu Kaushik; Mangal S Nagarsenker; Maneesh J Nerurkar
Journal:  AAPS PharmSciTech       Date:  2014-06-12       Impact factor: 3.246

8.  Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers.

Authors:  David J Brayden; Joanna Griffin
Journal:  Vet Res Commun       Date:  2007-06-20       Impact factor: 2.459

9.  Establishment of a P-glycoprotein substrate screening model and its preliminary application.

Authors:  Yi Wang; Jiang Cao; Su Zeng
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

10.  Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol.

Authors:  Anna Elgart; Irina Cherniakov; Yanir Aldouby; Abraham J Domb; Amnon Hoffman
Journal:  Pharm Res       Date:  2013-05-18       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.